Like you, we’ve been thinking a lot about COVID-19 (aka the coronavirus) lately, and the mountain of misinformation that has followed in its wake. While we concede we have stopped shaking people’s hands (which likely turned off more than a few folks at the Psychology-Law Society conference Jonathan spoke at last week), we’re struggling to figure out what is fact and what is fiction. We regret we can’t help you on that front. But we probably can lend a hand in understanding the impact of the current health emergency on your federal contracts.
Jonathan Aronie is a partner in the firm's Washington, D.C. office and leader of the firm's Government Contracts, Investigations and International Trade Practice Group and Organizational Integrity Group.
On August 13, 2018, President Trump signed into law the National Defense Authorization Act (NDAA) of 2019. While the annual NDAAs are tracked, analyzed, and picked apart with great care by the federal contracting community, the health care industry typically pays them little mind. But ignoring the 2019 NDAA would be a big mistake, because tucked within its more than 1,000 sections is one that will have a significant impact on many health care industry players. It’s known as Section 889. Read our thoughts on Section 889’s impact on the Health Care industry here.
Continue Reading Why the Health Care Industry Should Be Concerned About Section 889 of the 2019 National Defense Authorization Act